8-K

                        SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549


                                    FORM 8-K

                                CURRENT REPORT


       Pursuant to Section 13 or 15(d) of the Securities Exchange Act
                                   of 1934


      Date of Report (Date of earliest event reported) September 12, 2000


                        DIALYSIS CORPORATION OF AMERICA
            ------------------------------------------------------
            (Exact name of registrant as specified in its charter)

           Florida                  0-8527               59-1757642
- ----------------------------     -----------         -------------------
(State or other jurisdiction     (Commission           (IRS Employer
      of incorporation)          File Number)        Identification No.)

      27 Miller Avenue, Lemoyne, Pennsylvania            17043
     ----------------------------------------         ----------
     (Address of principal executive offices)         (Zip Code)

      Registrant's telephone number, including area code (717) 730-6164
                                                         --------------



Item 5.  Other Events

     The Company plans to acquire up to approximately 300,000 shares of its
outstanding trading stock, which presently is approximately 1,350,000 shares,
at current market prices.  This is based on management's belief that the
common stock, based on current market prices, is undervalued.  The purchases
will be funded from internally generated funds.  The press release, an
exhibit to this Current Report, provides more information with regard to the
repurchase program.


Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits

     (a)  Financial Statements of Businesses Acquired

          Not Applicable

     (b)  Pro Forma Financial Information

          Not Applicable

     (c)  Exhibits

          (99) Additional Exhibits

              (i) Press Release re: purchase of Company's common stock dated
                  September 12, 2000.

                               SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                       DIALYSIS CORPORATION OF AMERICA

                                          /s/ Stephen W. Everett

                                       By-------------------------------------
                                          STEPHEN W. EVERETT, President

Dated:  September 12, 2000



                              EXHIBIT INDEX


(99) Additional Exhibits

     (i) Press Release re: purchase of Company's common stock dated September
         12, 2000.

EX-99.1

     99(i) Press Release re: purchase of Company's common stock dated
           September 12, 2000.



                              Press Release

                    DIALYSIS CORPORATION OF AMERICA

                    DIALYSIS CORPORATION OF AMERICA
              ANNOUNCES PLAN TO PURCHASE ITS COMMON STOCK

Lemoyne, PA - September 12, 2000 - Dialysis Corporation of America (the
"Company") (NASDAQ-DCAI) announces its intent to acquire up to approximately
300,000 of its outstanding trading shares of common stock, which float
currently approximates 1,350,000 shares, at prevailing market prices.
Management believes its common stock, based on current market prices, is
undervalued.  The repurchases will be funded from internally generated funds.
However, the determination to repurchase common stock is not deemed to be a
recommendation to shareholders or others to purchase or sell the common stock
of the Company. The shares may be purchased from time to time in the open
market, in privately negotiated transactions or in block purchases.  The
common stock closed on Monday, September 11, 2000 at $.88.

Dialysis Corporation of America owns and operates free standing kidney
hemodialysis centers in Pennsylvania and New Jersey, providing patients with
a choice of a full range of quality in-center, acute or at-home hemodialysis
services.  The Company plans expansion in other states, and currently has two
new dialysis facilities under construction in Georgia and Ohio.

This release contains forward-looking statements that are subject to risks
and uncertainties, including but not limited to certain delays beyond the
Company's control with respect to future business events, the extent of
acquiring shares of common stock at current market prices, regulation of
dialysis operations, government rate determination for Medicare reimburse-
ment, the highly competitive environment in the operation and acquisition
of dialysis centers, the ability to develop additional dialysis facilities,
whether patient bases of the Company's dialysis facilities can expand to
provide profitability and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission.

CONTACT:  For more information, contact Thomas K. Langbein, CEO, Dialysis
Corporation of America, 777 Terrace Avenue, Hasbrouck Heights, NJ 07604.
Telephone Number (201) 288-8222.